Amphastar P (AMPH)

Sep 24, 2026

Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO William Peters sold 4,139 shares of the company's stock for a total of $103,475 under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Peters still directly owns 168,707 shares valued at approximately $4.2 million. The company recently reported strong quarterly earnings, significantly beating analyst estimates, although the consensus analyst rating remains "Reduce" with an average price target below the current trading price.

Sep 18, 2026

Amphastar Pharmaceuticals EVP Rong Zhou sold 10,000 shares of the company's stock for $239,400, reducing her direct holdings by 5.58% to 169,203 shares. Despite the sale, Amphastar reported strong quarterly earnings, beating EPS and revenue estimates. Analyst sentiment remains cautious, with a consensus "Reduce" rating and a target price of $22.50.

Sep 16, 2026

Squarepoint Ops LLC significantly increased its stake in Amphastar Pharmaceuticals, Inc. by 178% in the second quarter, now holding 78,795 shares valued at $1.59 million. Despite this increase in institutional investment, analysts maintain a cautious "Reduce" rating for AMPH with a consensus price target of $22.50. The company recently surpassed quarterly earnings and revenue expectations, but corporate insiders have sold shares totaling $421,047 during the last quarter.